Claro Advisors LLC Sells 609 Shares of ARK Genomic Revolution ETF (BATS:ARKG)

Claro Advisors LLC reduced its holdings in ARK Genomic Revolution ETF (BATS:ARKG) by 7.8% during the first quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 7,228 shares of the company’s stock after selling 609 shares during the quarter. Claro Advisors LLC’s holdings in ARK Genomic Revolution ETF were worth $208,000 at the end of the most recent quarter.

A number of other large investors have also recently made changes to their positions in ARKG. Principal Securities Inc. bought a new stake in shares of ARK Genomic Revolution ETF during the fourth quarter valued at approximately $32,000. Northwest Financial Advisors bought a new stake in shares of ARK Genomic Revolution ETF during the fourth quarter valued at approximately $47,000. Tidemark LLC bought a new stake in shares of ARK Genomic Revolution ETF during the fourth quarter valued at approximately $48,000. Naples Money Management LLC bought a new stake in shares of ARK Genomic Revolution ETF during the fourth quarter valued at approximately $63,000. Finally, ICA Group Wealth Management LLC bought a new stake in shares of ARK Genomic Revolution ETF during the fourth quarter valued at approximately $66,000.

ARK Genomic Revolution ETF Stock Performance

BATS ARKG opened at $22.89 on Wednesday. The company’s fifty day moving average price is $24.97 and its 200 day moving average price is $27.96.

ARK Genomic Revolution ETF Profile

The ARK Genomic Revolution ETF (ARKG) is an exchange-traded fund that mostly invests in stocks based on a particular theme. The fund is an actively managed fund that targets companies involved in the genomics industry. ARKG was launched on Oct 31, 2014 and is managed by ARK.